MalDA, Accelerating Malaria Drug Discovery
Name
1-s2.0-S147149222100012X-main.pdf
Description
Published version
Size
2.06 MB
Format
Unknown
Checksum (MD5)
b2755577d95378c51a9418ab2c7b3248
Author(s)
Yang, Tuo
Ottilie, Sabine
Istvan, Eva S
Godinez-Macias, Karla P
Lukens, Amanda K
Baragaña, Beatriz
Campo, Brice
Walpole, Chris
Niles, Jacquin C
Chibale, Kelly
Date Issued
February 2021
Journal
Trends in Parasitology
Publisher
Elsevier BV
Version
Final published version
Abstract
© 2021 The Authors The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.PT.2021.01.009
